- Home
- NGNE vs CURV Comparison
NGNE vs CURV Comparison
Compare NGNE & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- CURV
- Stock Information
- Founded
- NGNE 2003
- CURV 2001
- Country
- NGNE United States
- CURV United States
- Employees
- NGNE N/A
- CURV N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- CURV Clothing/Shoe/Accessory Stores
- Sector
- NGNE Health Care
- CURV Consumer Discretionary
- Exchange
- NGNE Nasdaq
- CURV Nasdaq
- Market Cap
- NGNE 325.3M
- CURV 215.9M
- IPO Year
- NGNE N/A
- CURV 2021
- Fundamental
- Price
- NGNE $18.48
- CURV $2.16
- Analyst Decision
- NGNE Strong Buy
- CURV Hold
- Analyst Count
- NGNE 7
- CURV 4
- Target Price
- NGNE $41.86
- CURV $4.00
- AVG Volume (30 Days)
- NGNE 110.1K
- CURV 482.6K
- Earning Date
- NGNE 08-11-2025
- CURV 09-04-2025
- Dividend Yield
- NGNE N/A
- CURV N/A
- EPS Growth
- NGNE N/A
- CURV N/A
- EPS
- NGNE N/A
- CURV 0.09
- Revenue
- NGNE N/A
- CURV $1,089,931,000.00
- Revenue This Year
- NGNE N/A
- CURV N/A
- Revenue Next Year
- NGNE N/A
- CURV N/A
- P/E Ratio
- NGNE N/A
- CURV $24.08
- Revenue Growth
- NGNE N/A
- CURV N/A
- 52 Week Low
- NGNE $6.88
- CURV $2.08
- 52 Week High
- NGNE $74.49
- CURV $7.25
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- CURV 35.39
- Support Level
- NGNE $19.59
- CURV $2.13
- Resistance Level
- NGNE $20.46
- CURV $2.24
- Average True Range (ATR)
- NGNE 1.23
- CURV 0.10
- MACD
- NGNE -0.20
- CURV 0.05
- Stochastic Oscillator
- NGNE 13.37
- CURV 38.30
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.